Fen Wang
- Cancer Research top 1%
- Cancer, Hypoxia, and Metabolism 17
- MicroRNA in disease regulation 14
- Cancer-related molecular mechanisms research 14
- Molecular Biology top 2%
- Fibroblast Growth Factor Research 26
- Epigenetics and DNA Methylation 15
- Kruppel-like factors research 13
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers 12
- Cell Biology top 2%
- Infectious Diseases top 2%
-
- Helicobacter pylori-related gastroenterology studies 11
Fen Wang
266 papers receiving 7.4k citations
Hit Papers
Peers
Comparison fields: 5 of 177
- Cancer Research 1.2k
- Molecular Biology 3.6k
- Oncology 1.2k
- Cell Biology 592
- Infectious Diseases 603
Countries citing papers authored by Fen Wang
This map shows the geographic impact of Fen Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fen Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fen Wang more than expected).
Fields of papers citing papers by Fen Wang
This network shows the impact of papers produced by Fen Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fen Wang. The network helps show where Fen Wang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Fen Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 5 | |
| 6 | 2024 | 11 | |
| 7 | 2023 | 11 | |
| 8 | 2023 | 1 | |
| 9 | 2023 | 6 | |
| 10 | 2022 | 13 | |
| 11 | Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinomabreakdown → | 2022 | 120 |
| 12 | 2022 | 15 | |
| 13 | 2021 | 8 | |
| 14 | 2020 | 19 | |
| 15 | 2018 | 17 | |
| 16 | Clinical observation of oxaliplatin-based regimen for sorafenib-resistant advanced primary liver carcinoma | 2014 | 2 |
| 17 | 2013 | 82 | |
| 18 | 2011 | 40 | |
| 19 | 2011 | 1 | |
| 20 | 2008 | 54 |
About Fen Wang
Fen Wang is a scholar working on Cancer Research, Oncology and Endocrinology, Diabetes and Metabolism, having authored 277 papers that have together received 7.5k indexed citations. Recurring topics across this work include Fibroblast Growth Factor Research (26 papers), Cancer, Hypoxia, and Metabolism (17 papers), Epigenetics and DNA Methylation (15 papers), MicroRNA in disease regulation (14 papers), Cancer-related molecular mechanisms research (14 papers), Kruppel-like factors research (13 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Helicobacter pylori-related gastroenterology studies (11 papers). The work is most often cited by research in Cancer Research (1.2k citations), Molecular Biology (3.6k citations) and Oncology (1.2k citations). Fen Wang has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Wallace L. McKeehan, Chengliu Jin, Chaofeng Yang, Xuefeng Yu, Huihui Ren, Yongli Yan, Xiaoli Shi, Shujun Zhang, Kun Dong and Jianping Jia. Their work appears in journals such as Journal of Clinical Oncology, Scientific Reports, Journal of Biological Chemistry, Oncology Reports and Frontiers in Endocrinology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.